![]() |
|
|
Vol. 298, Issue 3, 986-995, September 2001
-Aminobutyric Acid Type A (GABAA) Receptors: Mechanism
and Site of Action
Department of Pharmacology and Neuroscience, University of North
Texas Health Science Center, Fort Worth, Texas (R.Q.H., C.B.H., M.I.D.,
G.H.D.); Department of Molecular Biology and Pharmacology, Washington
University, St. Louis, Missouri (D.F.C.); and Cytovia, Inc., San Diego,
California (J.A.D.)
Pentylenetetrazole (PTZ) is a central nervous system convulsant
that is thought, based on binding studies, to act at the picrotoxin (PTX) site of the
-aminobutyric acid type A
(GABAA) receptor. In the present study, we have
investigated the mechanism and site of action of PTZ in recombinant
GABAA receptors. In rat
1
2
2 receptors, PTZ
inhibited GABA-activated Cl
current in a
concentration-dependent, voltage-independent manner, with an
IC50 of 0.62 ± 0.13 mM. The mechanism of inhibition
appeared competitive with respect to GABA in both rat and human
1
2
2 receptors. Varying subunit configuration (change or lack
of
subunit isoform or lack of
2 subunit) had modest effects on
PTZ-induced inhibition, as evidenced by comparable IC50
values (0.6-2.2 mM) in all receptor configurations tested. This
contrasts with PTX and other PTX-site ligands, which have greater
affinity in receptors lacking an
subunit. Using a one-site model
for PTZ interaction with
1
2
2 receptors, the association rate
(k+1) was found to be 1.14 × 103 M
1 s
1 and the dissociation
rate (k
1) was 0.476 s
1,
producing a functional kd of 0.418 mM. PTZ
could only gain access to its binding site extracellularly.
Single-channel recordings demonstrated that PTZ decreased open
probability by increasing the duration of closed states but had no
effect on single-channel conductance or open state duration.
-Isopropyl-
-methyl-
-butyrolactone, a compound known to
antagonize effects of PTX, also diminished the effects of PTZ. Taken
together, our results indicate that pentylenetetrazole and picrotoxin
interact with overlapping but distinct domains of the GABAA receptor.
This article has been cited by other articles:
![]() |
L. A. Gonzalez, M. B. Gatch, C. M. Taylor, C. L. Bell-Horner, M. J. Forster, and G. H. Dillon Carisoprodol-Mediated Modulation of GABAA Receptors: In Vitro and in Vivo Studies J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 827 - 837. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Suzuki, H. Miyamoto, T. Nakahari, I. Inoue, T. Suemoto, B. Jiang, Y. Hirota, S. Itohara, T. C. Saido, T. Tsumoto, et al. Efhc1 deficiency causes spontaneous myoclonus and increased seizure susceptibility Hum. Mol. Genet., March 15, 2009; 18(6): 1099 - 1109. [Abstract] [Full Text] [PDF] |
||||